AstraZeneca tops first Pharmaceutical Invention Index
The first annual Pharmaceutical Invention Index, released by IDEA Pharma ton Sunday, sees AstraZeneca top the industry for the novelty and breadth of its pipeline.
Released for the first time in 2019, at the Pharma Innovation Summit in Boca Raton, Florida, the Pharmaceutical Invention Index takes a focused look at the breadth and depth of novel agents currently being developed within the most innovative Pharma pipelines. Alongside the Pharmaceutical Innovation Index, which ranks companies for their ability to add value to or derive value from their pipeline, the Invention Index provides a more forward-looking view, of who is developing medicines that matter, embracing science and innovations in R&D.
The Pharmaceutical Invention Index consists of four key metrics: the proportion of pipeline to marketed drugs, the number of trials investigating novel agents, the proportion of 'novel' regulatory designations, and an assessment of the companies' R&D investments. Data are used to objectively evaluate each company and produce an independent category score for each of the top 30 companies. These scores are used to calculate an overall company score and provide an ordinal ranking.
AstraZeneca landed at top spot in the rankings, scoring exceptionally well across all four metrics. AstraZeneca boasted a high proportion of pipeline to marketed drugs, a large number of trials investigating novel drugs, a good proportion of 'novel' regulatory designations, and a healthy R&D investment track record, as well as a commitment to incremental systematic improvements.
Top-10 innovators
Company | FINAL RANKING |
AstraZeneca (LSE: AZN) | 1 |
Celgene (Nasdaq; CELG) | 2 |
Eli Lilly (NYSE: LLY) | 3 |
Novartis (NOVN: VX) | 4 |
AbbVie (NYSE: ABBV) | 5 |
Vertex (Nasdaq: VRTX) | 5 |
Bristol-Myers Squibb (NYSE: BMY) | 6 |
Regeneron (Nasdaq: REGN) | 7 |
Daiichi Sankyo (TYO: 4568) | 8 |
GSK (LSE: GSK) | 9 |
Biogen (Nasdaq: BIIB) | 10 |
Commenting on the index, IDEA Pharma's chief executive, Mike Rea said: "There's a critical distinction between invention and innovation – success is achieved by discovering and developing meaningfully great medicines (invention) and getting those medicines to market, and to patients (innovation). It is wonderful to see a company of AstraZeneca's scale and history able to turn around its fortunes in a relatively short period of time."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze